부산대학교 도서관

Baldoceda L; Robert C

SPERMOVA, Vol 7, Iss 1, Pp 27-31 (2017)

Ducrocq V; Robert C

Genetics Selection Evolution, Vol 28, Iss 1, Pp 51-65 (1996)

Ducrocq V; Foulley JL; Robert C

Genetics Selection Evolution, Vol 27, Iss 2, Pp 125-134 (1995)

Ducrocq V; Foulley JL; Robert C

Genetics Selection Evolution, Vol 27, Iss 2, Pp 111-123 (1995)

Emile J; Service of Dermatology, Gustave Roussy, Université Paris Saclay, Villejuif, France.; Cauquil C; Department of Neurology, CHU Bicetre, APHP, Le Kremlin Bicêtre, France.; Carpentier D; Medical Intensive Care Unit, CHU des hôpitaux de Rouen, Rouen, France.; Routier E; Service of Dermatology, Gustave Roussy, Université Paris Saclay, Villejuif, France.; Robert C; Service of Dermatology, Gustave Roussy, Université Paris Saclay, Villejuif, France. Electronic address: caroline.robert@gustaveroussy.fr.

Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

Chargari C; Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.; INSERM1030 Molecular Radiotherapy and Therapeutic Innovation Gustave Roussy Cancer Campus, Villejuif 94805, France.; Maury P; Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.; INSERM1030 Molecular Radiotherapy and Therapeutic Innovation Gustave Roussy Cancer Campus, Villejuif 94805, France.; Texier M; Biostatistics Unit, Gustave Roussy Cancer Campus, Villejuif 94805, France.; Genestie C; Department of Pathology, Gustave Roussy Cancer Campus, Villejuif 94805, France.; Morice P; Department of Surgery, Gustave Roussy Cancer Campus, Villejuif 94805, France.; Bockel S; Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.; INSERM1030 Molecular Radiotherapy and Therapeutic Innovation Gustave Roussy Cancer Campus, Villejuif 94805, France.; Gouy S; Department of Surgery, Gustave Roussy Cancer Campus, Villejuif 94805, France.; Ba M; Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.; Achkar S; Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.; Lux F; Institut Lumière-Matière, UMR 5306, Université Lyon1-CNRS, Université de Lyon, Villeurbanne Cedex 69622 Villeurbanne, France.; Institut Universitaire de France, 75231 Paris, France.; Tillement O; Institut Lumière-Matière, UMR 5306, Université Lyon1-CNRS, Université de Lyon, Villeurbanne Cedex 69622 Villeurbanne, France.; Dufort S; NH TherAguix SA, 38240 Meylan, France.; Duc GLE; NH TherAguix SA, 38240 Meylan, France.; Debeaumont O; NH TherAguix SA, 38240 Meylan, France.; Massard C; Université Paris-Saclay, CNRS, Institut des Sciences Moléculaires d'Orsay, 91405 Orsay, France.; Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy Cancer Campus, Villejuif 94805, France.; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.; University Paris-Saclay Faculty of Medicine, Le Kremlin, Bicêtre 94270, France.; Maulard A; Department of Pathology, Gustave Roussy Cancer Campus, Villejuif 94805, France.; Porcel E; Université Paris-Saclay, CNRS, Institut des Sciences Moléculaires d'Orsay, 91405 Orsay, France.; Bahleda R; Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy Cancer Campus, Villejuif 94805, France.; Ammari S; Department of Radiology, Gustave Roussy Cancer Campus, Villejuif 94805, France.; Morel D; Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.; INSERM1030 Molecular Radiotherapy and Therapeutic Innovation Gustave Roussy Cancer Campus, Villejuif 94805, France.; Espenel S; Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.; Pautier P; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.; Robert C; Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.; INSERM1030 Molecular Radiotherapy and Therapeutic Innovation Gustave Roussy Cancer Campus, Villejuif 94805, France.; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.; University Paris-Saclay Faculty of Medicine, Le Kremlin, Bicêtre 94270, France.; Deutsch E; Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.; INSERM1030 Molecular Radiotherapy and Therapeutic Innovation Gustave Roussy Cancer Campus, Villejuif 94805, France.; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.; University Paris-Saclay Faculty of Medicine, Le Kremlin, Bicêtre 94270, France.

Publisher: American Chemical Society Country of Publication: United States NLM ID: 101313589 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1936-086X (Electronic) Linking ISSN: 19360851 NLM ISO Abbreviation: ACS Nano Subsets: MEDLINE

Long GV; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Hauschild A; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Santinami M; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Kirkwood JM; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Atkinson V; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Mandala M; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Merelli B; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Sileni VC; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Nyakas M; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Haydon A; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Dutriaux C; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Robert C; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Mortier L; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Schachter J; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Schadendorf D; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Lesimple T; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Plummer R; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Larkin J; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Tan M; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Adnaik SB; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Burgess P; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Jandoo T; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.; Dummer R; From the Melanoma Institute Australia, the University of Sydney, Royal North Shore Hospital, and Mater Hospital, Sydney (G.V.L.), Princess Alexandra Hospital, the Gallipoli Medical Research Foundation, and the University of Queensland, Woolloongabba (V.A.), and Alfred Hospital, Melbourne, VIC (A.H.) - all in Australia; the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel (A.H.), and the German Cancer Consortium, National Center for Tumor Diseases, University Hospital Essen, Campus Essen, and the University Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen (D.S.) - all in Germany; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan (M.S.), the Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo (B.M., M.M.), and Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua (V.C.S.) - all in Italy; the Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.); Oslo University Hospital and the Norwegian Radium Hospital, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux and Hôpital Saint-André, Bordeaux (C.D.), Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Université de Lille, INSERM Unité 1189, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; the Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, and the Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel (J.S.); Northern Centre for Cancer Care, Freeman Hospital, and Newcastle University, Newcastle (R.P.), and the Royal Marsden National Health Services Foundation Trust, London (J.L.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (M.T.); Novartis Healthcare, Hyderabad, India (S.B.A., T.J.); and Novartis Pharma, Basel (P.B.), and the University Hospital Zürich Skin Cancer Center, Zurich (R.D.) - both in Switzerland.

Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

Villegas F; Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden; Radiotherapy Physics and Engineering, Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Solna, Sweden.; Dal Bello R; Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.; Alvarez-Andres E; OncoRay - National Center for Radiation Research in Oncology, Medical Faculty and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany; Faculty of Medicine Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.; Dhont J; Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Department of Medical Physics, Brussels, Belgium; Université Libre De Bruxelles (ULB), Radiophysics and MRI Physics Laboratory, Brussels, Belgium.; Janssen T; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Milan L; Medical Physics Unit, Imaging Institute of Southern Switzerland (IIMSI), Ente Ospedaliero Cantonale, Bellinzona, Switzerland.; Robert C; UMR 1030 Molecular Radiotherapy and Therapeutic Innovations, ImmunoRadAI, Paris-Saclay University, Institut Gustave Roussy, Inserm, Villejuif, France; Department of Radiation Oncology, Gustave Roussy, Villejuif, France.; Salagean GA; Faculty of Physics, Babes-Bolyai University, Cluj-Napoca, Romania; Department of Radiation Oncology, TopMed Medical Centre, Targu Mures, Romania.; Tejedor N; Department of Medical Physics and Radiation Protection, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.; Trnková P; Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria.; Fusella M; Department of Radiation Oncology, Abano Terme Hospital, Italy.; Placidi L; Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Rome, Italy. Electronic address: lorenzo.placidi@policlinicogemelli.it.; Cusumano D; Mater Olbia Hospital, Strada Statale Orientale Sarda 125, Olbia, Sassari, Italy.

Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8407192 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0887 (Electronic) Linking ISSN: 01678140 NLM ISO Abbreviation: Radiother Oncol Subsets: MEDLINE

Librado P; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France. pablo.librado@ibe.upf-csic.es.; Institut de Biologia Evolutiva (CSIC - Universitat Pompeu Fabra), Barcelona, Spain. pablo.librado@ibe.upf-csic.es.; Tressières G; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France.; Chauvey L; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France.; Fages A; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France.; Zoological institute, Department of Environmental Sciences, University of Basel, Vesalgasse 1, Basel, Switzerland.; Khan N; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France.; Department of Biotechnology, Abdul Wali Khan University, Mardan, Pakistan.; Schiavinato S; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France.; Calvière-Tonasso L; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France.; Kusliy MA; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France.; Department of the Diversity and Evolution of Genomes, Institute of Molecular and Cellular Biology SB RAS, 8/2 Academician Lavrentiev Avenue, Novosibirsk, Russia.; Gaunitz C; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France.; Lundbeck Foundation GeoGenetics Centre, Globe Institute, University of Copenhagen, Copenhagen, Denmark.; Liu X; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France.; Wagner S; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France.; INRAE Division Ecology and Biodiversity (ECODIV), Plant Genomic Resources Center (CNRGV), 24 Chemin de Borde Rouge - Auzeville, Castanet Tolosan Cedex, France.; Der Sarkissian C; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France.; Seguin-Orlando A; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France.; Perdereau A; Genoscope, Institut de Biologie François Jacob, CEA, CNRS, Université d'Évry, Université Paris-Saclay, Évry, France.; Aury JM; Génomique Métabolique, Genoscope, Institut François Jacob, CEA, CNRS, Univ Évry, Université Paris-Saclay, Évry, France.; Southon J; Department of Earth System Science, University of California, Irvine, Irvine, CA, USA.; Shapiro B; Department of Ecology and Evolutionary Biology, University of California Santa Cruz, Santa Cruz, CA, USA.; Bouchez O; INRAE, GeT-PlaGe, Genotoul, Castanet-Tolosan, France.; Donnadieu C; INRAE, GeT-PlaGe, Genotoul, Castanet-Tolosan, France.; Collin YRH; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France.; Taku Skan Skan Wasakliyapi: Global Institute for Traditional Sciences, 522 Seventh Street, Suite 202, Rapid City, South Dakota, USA.; Gregersen KM; The Royal Danish Academy, Institute of Conservation, Philip de Langes Allé 10, Copenhagen K, Denmark.; Jessen MD; National Museum of Denmark, Department for Prehistory, Middle Ages and Renaissance, Ny Vestergade 10, Copenhagen K, Denmark.; Christensen K; Museum Vestsjælland, Forten 10, Holbæk, Denmark.; Claudi-Hansen L; Museum Vestsjælland, Forten 10, Holbæk, Denmark.; Pruvost M; UMR 5199 De la Préhistoire à l'Actuel: Culture, Environnement et Anthropologie (PACEA), CNRS, Université de Bordeaux, Pessac Cédex, France.; Pucher E; Museum of Natural History, Burgring 7, Vienna, Austria.; Vulic H; Vinkovci Municipal Museum, Trg bana Josipa Šokčevića 16, Vinkovci, Croatia.; Novak M; Centre for Applied Bioanthropology, Institute for Anthropological Research, Ljudevita Gaja 32, Zagreb, Croatia.; Rimpf A; Ilok Town Museum, Šetalište o. Mladena Barbarića 5, Ilok, Croatia.; Turk P; Narodni muzej Slovenije, Prešernova 20, Ljubljana, Slovenia.; Reiter S; Institute of Animal Breeding and Genetics, Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Veterinärplatz 1, Vienna, Austria.; Brem G; Institute of Animal Breeding and Genetics, Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Veterinärplatz 1, Vienna, Austria.; Schwall C; Leibniz-Zentrum für Archäologie (LEIZA), Ludwig-Lindenschmit-Forum 1, Mainz, Germany.; Department of Prehistory & Western Asian/Northeast African Archaeology, Austrian Archaeological Institute (OeAI), Austrian Academy of Sciences (OeAW), Dominikanerbastei 16, Vienna, Austria.; Barrey É; Université Paris-Saclay, AgroParisTech, INRAE, GABI UMR1313, Jouy-en-Josas, France.; Robert C; Université Paris-Saclay, AgroParisTech, INRAE, GABI UMR1313, Jouy-en-Josas, France.; Ecole Nationale Vétérinaire d'Alfort, 7 Av du Général De Gaulle, Maisons-Alfort, France.; Degueurce C; Ecole Nationale Vétérinaire d'Alfort, 7 Av du Général De Gaulle, Maisons-Alfort, France.; Horwitz LK; National Natural History Collections, Edmond J. Safra Campus, Givat Ram, The Hebrew University, Jerusalem, Israel.; Klassen L; Museum Østjylland, Søndergade 1, Grenaa, Denmark.; Rasmussen U; Moesgaard Museum, Department of Archaeology, Moesgaard Allé 20, Højbjerg, Denmark.; Kveiborg J; Moesgaard Museum, Department of Archaeological Science and Conservation, Moesgaard Allé 15, Højbjerg, Denmark.; Johannsen NN; Department of Archaeology and Heritage Studies, Aarhus University, Højbjerg, Denmark.; Makowiecki D; Institute of Archaeology, Faculty of History, Nicolaus Copernicus University, Toruń, Poland.; Makarowicz P; Faculty of Archaeology, Adam Mickiewicz University, Poznań, Poland.; Szeliga M; Institute of Archaeology, Maria Curie-Skłodowska University, Lublin, Poland.; Ilchyshyn V; Kremenetsko-Pochaivskii Derzhavnyi Istoriko-arkhitekturnyi Zapovidnik, Kremenets, Kozubskogo 6, , Ukraine.; Rud V; Institute of Archaeology, National Academy of Sciences of Ukraine, Volodymyr Ivasiuk Avenue 12, Kyiv, Ukraine.; Romaniszyn J; Faculty of Archaeology, Adam Mickiewicz University, Poznań, Poland.; Mullin VE; Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland.; Verdugo M; Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland.; Bradley DG; Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland.; Cardoso JL; ICArEHB, Campus de Gambelas, University of Algarve, Faro, Portugal.; Universidade Aberta, Lisbon, Portugal.; Valente MJ; Faculdade de Ciências Humanas e Sociais, Centro de Estudos de Arqueologia, Artes e Ciências do Património, Universidade do Algarve, Faro, Portugal.; Antunes MT; Centre for Research on Science and Geological Engineering, Universidade Nova de Lisboa, Lisbon, Portugal.; Ameen C; Department of Archaeology and History, University of Exeter, Exeter, UK.; Thomas R; School of Archaeology and Ancient History, University of Leicester, University Road, Leicester, UK.; Ludwig A; Department of Evolutionary Genetics, Leibniz-Institute for Zoo and Wildlife Research, Berlin, Germany.; Albrecht Daniel Thaer-Institute, Faculty of Life Sciences, Humboldt University Berlin, Berlin, Germany.; Marzullo M; Università degli Studi di Milano, Dipartimento di Beni Culturali e Ambientali, Milan, Italy.; Prato O; Università degli Studi di Milano, Dipartimento di Beni Culturali e Ambientali, Milan, Italy.; Gianni GB; Università degli Studi di Milano, Dipartimento di Beni Culturali e Ambientali, Milan, Italy.; Tecchiati U; Università degli Studi di Milano, Dipartimento di Beni Culturali e Ambientali, Milan, Italy.; Granado J; Basel University, Department of Environmental Sciences, Integrative Prehistory and Archaeological Science, Basel, Switzerland.; Schlumbaum A; Basel University, Department of Environmental Sciences, Integrative Prehistory and Archaeological Science, Basel, Switzerland.; Deschler-Erb S; Basel University, Department of Environmental Sciences, Integrative Prehistory and Archaeological Science, Basel, Switzerland.; Mráz MS; Basel University, Department of Environmental Sciences, Integrative Prehistory and Archaeological Science, Basel, Switzerland.; Boulbes N; Institut de Paléontologie Humaine, Fondation Albert Ier, Paris/UMR 7194 HNHP, MNHN-CNRS-UPVD/EPCC Centre Européen de Recherche Préhistorique, Tautavel, France.; Gardeisen A; Centre National de Recherche Scientifique, Archéologie des Sociétés Méditeranéennes, Archimède IA-ANR-11-LABX-0032-01, Université Paul Valéry, Montpellier, France.; Mayer C; Federal Monuments Authority Austria, Department for Digitalization and Knowledge Transfer, Vienna, Austria.; Döhle HJ; Landesamt für Denkmalpflege und Archäologie Sachsen-Anhalt - Landesmuseum für Vorgeschichte, Halle (Saale), Germany.; Vicze M; National Institute of Archaeology, Hungarian National Museum, Budapest, Hungary.; Kosintsev PA; Paleoecology Laboratory, Institute of Plant and Animal Ecology, Ural Branch of the Russian Academy of Sciences, Ekaterinburg, Russia.; Department of History of the Institute of Humanities, Ural Federal University, Ekaterinburg, Russia.; Kyselý R; Department of Natural Sciences and Archaeometry, Institute of Archaeology of the Czech Academy of Sciences, Letenská 4, Prague 1, Czechia.; Peške L; Professional biological consultant, Moskevská 61, Prague 10, Czechia.; O'Connor T; Department of Archaeology, University of York, c/o Kings Manor, York, UK.; Ananyevskaya E; Department of Archaeology, History Faculty, Vilnius University, Vilnius, Lithuania.; Shevnina I; Laboratory for Archaeological Research, Akhmet Baitursynuly Kostanay Regional University, Kostanay, Kazakhstan.; Logvin A; Laboratory for Archaeological Research, Akhmet Baitursynuly Kostanay Regional University, Kostanay, Kazakhstan.; Kovalev AA; Department of Archaeological Heritage Preservation, Institute of Archaeology of the Russian Academy of Sciences, Dm. Ulyanov Street, 19, Moscow, Russia.; Iderkhangai TO; Department of Innovation and Technology, Ulaanbaatar Science and Technology Park, National University of Mongolia, Bayanzurkh district, Luvsantseveen street, 5th khoroo, Ulaanbaatar, Mongolia.; Sablin MV; Zoological Institute, Russian Academy of Sciences, University Quay, 1, St Petersburg, Russia.; Dashkovskiy PK; Department of Russian Regional Studies, National and State-confessional Relations, Altai State University, Prospekt Lenina, 61, Barnaul, Russia.; Graphodatsky AS; Department of the Diversity and Evolution of Genomes, Institute of Molecular and Cellular Biology SB RAS, 8/2 Academician Lavrentiev Avenue, Novosibirsk, Russia.; Merts I; Toraighyrov University, Joint Research Center for Archeological Studies, Avenue Lomova 64, Pavlodar, Kazakhstan.; Department of Archaeology, Ethnography and Museology, Altai State University, Prospekt Lenina, 61, Barnaul, Russia.; Merts V; Toraighyrov University, Joint Research Center for Archeological Studies, Avenue Lomova 64, Pavlodar, Kazakhstan.; Kasparov AK; Institute of the History of Material Culture, Russian Academy of Sciences, 18 Dvortsovaya Emb., St. Petersburg, Russian Federation.; Pitulko VV; Institute of the History of Material Culture, Russian Academy of Sciences, 18 Dvortsovaya Emb., St. Petersburg, Russian Federation.; Peter the Great Museum of Anthropology and Ethnography (Kunstkamera), Russian Academy of Sciences, 3, Universitetskaya nab., St Petersburg, Russia.; Onar V; Osteoarchaeology Practice and Research Center and Department of Anatomy, Faculty of Veterinary Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye.; Öztan A; Archaeology Department, Ankara University, Ankara, Türkiye.; Arbuckle BS; Department of Anthropology, Alumni Building, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; McColl H; Lundbeck Foundation GeoGenetics Centre, Globe Institute, University of Copenhagen, Copenhagen, Denmark.; Renaud G; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France.; Department of Health Technology, Section for Bioinformatics, Technical University of Denmark (DTU), Copenhagen, Denmark.; Khaskhanov R; Kh. Ibragimov Complex Institute of the Russian Academy of Sciences (CI RAS), 21 a V. Alieva (Staropromyslovskoe highway), Grozny, Chechen Republic, Russia.; Demidenko S; Institute of Archaeology, Russian Academy of Sciences, Dm. Uljanova, 19, Moscow, Russia.; Kadieva A; State Historical Museum, Department of Archaeological Monuments, Moscow, Red Square 1, Moscow, Russian Federation.; Atabiev B; Institute for Caucasus Archaeology, Ul. Katkhanova 30, Nalchik, Russian Federation.; Sundqvist M; Östra Greda Research Group, Vialmvägen 5, Borgholm, Sweden.; Lindgren G; Department of Animal Breeding and Genetics, Swedish University of Agricultural Sciences, Uppsala, Sweden.; Center for Animal Breeding and Genetics, Department of Biosystems, KU Leuven, Leuven, Belgium.; López-Cachero FJ; Institut d'Arqueologia de la Universitat de Barcelona (IAUB), Seminari d'Estudis i Recerques Prehistoriques (SERP-UB), Universitat de Barcelona (UB), Barcelona, Spain.; Albizuri S; Institut d'Arqueologia de la Universitat de Barcelona (IAUB), Seminari d'Estudis i Recerques Prehistoriques (SERP-UB), Universitat de Barcelona (UB), Barcelona, Spain.; Trbojević Vukičević T; Department of Anatomy, Histology and Embryology, Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, Zagreb, Croatia.; Rapan Papeša A; Vinkovci Municipal Museum, Trg bana Josipa Šokčevića 16, Vinkovci, Croatia.; Burić M; Department of Archaeology, Faculty of Humanities and Social Sciences, University of Zagreb, I. Lučića 3, Zagreb, Croatia.; Rajić Šikanjić P; Institute for Anthropological Research, Ljudevita Gaja 32, Zagreb, Croatia.; Weinstock J; Faculty of Arts and Humanities (Archaeology), University of Southampton, Southampton, UK.; Vilaró DA; Secció de Prehistòria i Arqueologia, IAUB Institut d'Arqueologia de la Universitat de Barcelona, C/Montalegre 6-8, Barcelona, Spain.; Codina F; C/Major, 20, La Tallada d'Empordà, , Spain.; Dalmau CG; Mosaïques Archéologie, Espace d'activités de la Barthe, Cournonterral, France.; de Llorens JM; Mon IberRocs SCL, Carrer Sta Anna 28, Vilanova i la Geltrú (Barcelona), Spain.; Pou J; Ajuntament de Calafell, Plaça Catalunya, 1, Calafell (Tarragona), Spain.; de Prado G; Museu d'Arqueologia de Catalunya (MAC-Ullastret), Afores s/n, Puig de Sant Andreu, Ullastret, Spain.; Sanmartí J; IEC-Institut d'Estudis Catalans (Union Académique Internationale), Carrer Del Carme, 47, Barcelona, Spain.; Departament d'Història i Arqueologia, Facultat de Geografia i Història, Universitat de Barcelona, Carrer Montalegre 6-8, Barcelona, Spain.; Kallala N; Ecole Tunisienne d'Histoire et d'Anthropologie, , Tunisia.; University of Tunis, Institut National du Patrimoine, Tunis, Tunisia.; Torres JR; Consell Insular d'Eivissa, Avenida de España 49, Eivissa, Illes Balears, Spain.; Maraoui-Telmini B; University of Tunis, Institut National du Patrimoine, Tunis, Tunisia.; Belarte Franco MC; IEC-Institut d'Estudis Catalans (Union Académique Internationale), Carrer Del Carme, 47, Barcelona, Spain.; ICREA, Catalan Institution for Research and Advanced Studies, Passeig Lluís Companys 23, Barcelona, Spain.; ICAC (Catalan Institute of Classical Archaeology), Pl. del Rovellat, s/n., Tarragona, Spain.; Valenzuela-Lamas S; Archaeology of Social Dynamics (ASD, 2021SGR_00501), Institució Milà i Fontanals, Consejo Superior de Investigaciones Científicas (IMF-CSIC), C/Egipcíaques 15, Barcelona, Spain.; UNIARQ - Unidade de Arqueologia, Universidade de Lisboa, Alameda da Universidade, Lisboa, Portugal.; Zazzo A; Centre National de Recherche Scientifique, Muséum national d'Histoire naturelle, Archéozoologie, Archéobotanique (AASPE), CP 56, Paris, France.; Lepetz S; Centre National de Recherche Scientifique, Muséum national d'Histoire naturelle, Archéozoologie, Archéobotanique (AASPE), CP 56, Paris, France.; Duchesne S; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France.; Alexeev A; Institute for Humanities Research and Indigenous Studies of the North (IHRISN), Petrovskogo St. 1, Yakutsk, Russia.; Bayarsaikhan J; Max Planck Institute of Geoanthropology, Kahlaische Str. 10, Jena, Germany.; Institute of Archaeology, Mongolian Academy of Science, Ulaanbaatar, Mongolia.; Houle JL; Department of Folk Studies and Anthropology, Western Kentucky University, Bowling Green, USA.; Bayarkhuu N; Archaeological Research Center and Department of Anthropology and Archaeology, National University of Mongolia, Ulaanbaatar, Mongolia.; Turbat T; Archaeological Research Center and Department of Anthropology and Archaeology, National University of Mongolia, Ulaanbaatar, Mongolia.; Crubézy É; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France.; Shingiray I; Faculty of History, University of Oxford, George Street, Oxford, UK.; Mashkour M; Centre National de Recherche Scientifique, Muséum national d'Histoire naturelle, Archéozoologie, Archéobotanique (AASPE), CP 56, Paris, France.; University of Tehran, Central Laboratory, Bioarchaeology Laboratory, Archaeozoology section, Jalalieh street 6, Tehran, Iran.; Berezina NY; Research Institute and Museum of Anthropology, Lomonosov Moscow State University, Moscow, Russia.; Korobov DS; Institute of Archaeology, Russian Academy of Sciences, Dm. Uljanova, 19, Moscow, Russia.; Belinskiy A; Nasledie Cultural Heritage Unit, Stavropol, Russia.; Kalmykov A; Nasledie Cultural Heritage Unit, Stavropol, Russia.; Demoule JP; UMR du CNRS 8215 Trajectoires, Institut d'Art et Archéologie, 3 rue Michelet, Paris, France.; Reinhold S; Eurasia Department of the German Archaeological Institute, Berlin, Germany.; Hansen S; Eurasia Department of the German Archaeological Institute, Berlin, Germany.; Wallner B; Institute of Animal Breeding and Genetics, Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Veterinärplatz 1, Vienna, Austria.; Roslyakova N; Department of Russian History and Archaeology, Samara State University of Social Sciences and Education, Samara, Russia.; Kuznetsov PF; Department of Russian History and Archaeology, Samara State University of Social Sciences and Education, Samara, Russia.; Tishkin AA; Department of Archaeology, Ethnography and Museology, Altai State University, Prospekt Lenina, 61, Barnaul, Russia.; Wincker P; Génomique Métabolique, Genoscope, Institut François Jacob, CEA, CNRS, Univ Évry, Université Paris-Saclay, Évry, France.; Kanne K; Department of Archaeology and History, University of Exeter, Exeter, UK.; School of Archaeology, University College Dublin, Dublin, Ireland.; Outram A; Department of Archaeology and History, University of Exeter, Exeter, UK.; Orlando L; Centre d'Anthropobiologie et de Génomique de Toulouse, CNRS UMR 5288, Université Paul Sabatier, Faculté de Médecine Purpan, 37 Allées Jules Guesde, Toulouse, France. ludovic.orlando@univ-tlse3.fr.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE

Morel D; Department of Radiation Oncology, Gustave Roussy, Villejuif, France.; INSERM U1030, Molecular Radiotherapy, Villejuif, France.; Robert C; Department of Radiation Oncology, Gustave Roussy, Villejuif, France.; INSERM U1030, Molecular Radiotherapy, Villejuif, France.; Paris-Saclay University, School of Medicine, Le Kremlin Bicêtre, France.; Paragios N; Therapanacea, Paris, France.; CentraleSupélec, Gif-sur-Yvette, France.; Grégoire V; Department of Radiation Oncology, Centre Léon Bérard, Lyon, France.; Deutsch E; Department of Radiation Oncology, Gustave Roussy, Villejuif, France.; INSERM U1030, Molecular Radiotherapy, Villejuif, France.; Paris-Saclay University, School of Medicine, Le Kremlin Bicêtre, France.

Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE